Weight Loss with Tirzepatide Injections at our Houston Clinic

Weight Loss doesn’t have to be difficult anymore! If you’re struggling with weight loss despite dieting, and exercising, we can help you! Discover the game-changing Tirzepatide injections at the best weight loss clinic in Houston!  

What Is Tirzepatide? 

Tirzepatide is a new injection for chronic weight management in adults with obesity or overweight adults with at least one weight related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). It is approved in the USA, Europe, Japan, and other countries. 

Our Houston weight loss clinic is proudly collaborating with an MD to offer compounded Tirzepatide (the active agent in  Mounjaro® injections and Zepbound®injections houston).

Proven Benefits of Tirzepatide Injection

• Significant Weight Loss: Clinical trials showed an average weight loss of up to 20.9% (52.0 lb) for patients without diabetes^1–4.
• Management of Type 2 Diabetes: Type 2 diabetic patients experienced up to 14.7% weight loss (13.7 to 28.4 lb) in clinical trials^5–7
• Improved Glycemic Control: Reduces hemoglobin A1c levels by up to 2.59%⁷.

• Improved Cardiometabolic Health: Improved waist circumference, blood pressure, HbA1c levels, lipid levels (cholesterol, triglyceride...) , as well as improved insulin sensitivity
•   Sustained Results: Proven weight loss as early as 4 weeks and maintained weight loss for up to 2 years, when combined with a reduced-calorie diet and increased physical activity^6,8.

How Tirzepatide Weight Loss Injections Work

Tirzepatide mimics the hormones GLP-1 and GIP. Administered once weekly, it works by: 

• Reducing appetite and food intake⁹.

• Increases insulin release from the pancreas, optimizing blood sugar control

•   Improves how the body uses insulin

• Slows down digestion, making you feel full longer.

Tirzepatide (Mounjaro) Side Effects

While the benefits are promising, Mounjaro® and Zepbound® (Tirzepatide) injections can also cause side effects like:

• Nausea 
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Hypoglycemia (especially with other diabetes medications)
• Rarely, pancreatitis. 

Please note: Side effects are dose dependent , and may vary among individuals.

 Who Should Avoid Tirzepatide Weight Loss Injections?

Tirzepitide (the active agent in Mounjaro® and Zepbound®) isn’t for everyone. Tirzepatide is not indicated for use in patients with:

•  Type 1 diabetes 

• Patients with a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Patients allergic to Tirzepatide or any of its excipients

• Patients who suffer any severe gastrointestinal disease

Please share your complete medical history with our MD, and they will determine If you are eligible for these weight loss injections in our Houston Clinic. 

Why Should You Choose Live Lean for Your Weight Loss Injections?

At our weight loss clinic in Houston, we offer personalized programs to help you achieve your weight loss goals and acquire healthy habits, along with the medical support and guidance you need!

 Here’s why we are the best choice for your Tirzepatide injections:

·Personalized weight loss programs: We will provide you with exact quantities to consume, recommendations for healthy products, as well as easy recipes to help you reach your weight loss goals faster. We have successfully helped over 3,700 clients to date! 

· Body composition tracking: Ensure you're losing fat, not muscle, by tracking your body composition beyond just the scale.

· Learn Healthy Habits: Learn to make healthier choices with our support. From picking the healthiest bread at the grocery store to mastering ordering at restaurants.

·Support in weaning off Tirzepatide injections: We help you maintain weight loss and develop healthy habits to prevent regaining weight after stopping the injections.

Take Control of Your Weight Today!

Are you ready to finally lose weight and live the life you have dreamed of? Contact us today to schedule a consultation and learn more about how we can help you achieve your weight loss goals.

References

1. Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & SURMOUNT-4 Investigators. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945

2. Tan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., Chung, H. C., Young, D. Y., Chan, M. Y., Khoo, C. M., Mehta, A., Muthiah, M. D., Noureddin, M., Ng, C. H., Chew, N. W. S., & Chin, Y. H. (2023). Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. International Journal of Obesity, 47(8), 677–685. https://doi.org/10.1038/s41366-023-01321-5

3. Jastreboff Ania M., Aronne Louis J., Ahmad Nadia N., Wharton Sean, Connery Lisa, Alves Breno, Kiyosue Arihiro, Zhang Shuyu, Liu Bing, Bunck Mathijs C., & Stefanski Adam. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

4. le Roux, C. W., Zhang, S., Aronne, L. J., Kushner, R. F., Chao, A. M., Machineni, S., Dunn, J., Chigutsa, F. B., Ahmad, N. N., & Bunck, M. C. (2023). Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity, 31(1), 96–110. https://doi.org/10.1002/oby.23612

5. Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., Benabbad, I., Zhang, X. M., Abalos, F. H., Manghi, F. C. P., Zaidman, C. J., Vico, M. L., Aizenberg, D., Costanzo, P. R., Serra, L. P., … Jones, T. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X

6. Vázquez, L. A., Tofé-Povedano, S., Bellido-Guerrero, D., Botella-Serrano, M., Soto-González, A., Mezquita-Raya, P., Delgado, E., Fajardo-Montañana, C., Morales-Portillo, C., Causanilles, A., Rubio-de Santos, M., Romera, I., & Jódar-Gimeno, E. (2024). Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects. Diabetes Therapy, 15(7), 1501–1512. https://doi.org/10.1007/s13300-024-01587-6

7. De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023). Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes, Obesity and Metabolism, 25(1), 3–17. https://doi.org/10.1111/dom.14831

8. Del Prato, S., Kahn, S., Pavo, I., Weerakkody, G., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A., Riesmeyer, J., Heine, R., Wiese, R., Ahmann, A., Arora, S., Ball, E., Calderon, R., Butuk, D., Chaychi, L., Chen, M., Curtis, B., & Kotsa, K. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398. https://doi.org/10.1016/S0140-6736(21)02188-7

9. Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021). Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 106(2), 388–396. https://doi.org/10.1210/clinem/dgaa863